Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 300.00
Bid: 298.00
Ask: 301.00
Change: 0.00 (0.00%)
Spread: 3.00 (1.007%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 300.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

21 Jun 2012 11:31

RNS Number : 8748F
Oxford Biomedica PLC
21 June 2012
 



Financial Services Authority

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

 

Oxford Biomedica Plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Full name of person(s) subject to thenotification obligation:

Legal & General Group Plc (L&G)

4. Full name of shareholder(s)  (if different from 3.):

N/A

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

 

19 June 2012

6. Date on which issuer notified:

20 June 2012

7. Threshold(s) that is/are crossed orreached:

 

L&G (Below 3%)

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

 

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

Ordinary 1p

 21,605,215

 

(As on 16/06/2010)

Below 3%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate

 

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

 

Exercise price

 

Expiration date

 

Exercise/Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 

Below 3%

 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group)

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect)

Legal & General Investment Management Limited (Indirect) (LGIM)

Legal & General Group Plc (Direct) (L&G) (Below 3% = LGAS, LGPL & PMC)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Insurance Holdings Limited (Direct) (LGIH)

Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Assurance Society Limited (LGAS & LGPL)

Legal & General Pensions Limited (Direct) (LGPL)

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will ceaseto hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

13. Additional information:

Notification using the total voting rights figure of  944,875,557

 

14. Contact name:

Paul Toon (LGIM)

15. Contact telephone number:

020 3124 3854

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUAURRUKANUAR
Date   Source Headline
29th Aug 20177:00 amRNSStuart Paynter starts as new CFO
24th Aug 201710:41 amRNSHardman Research: Ready for CTL019 approval
23rd Aug 201710:31 amRNSDirector Dealings / Market Share Purchase
22nd Aug 201710:35 amRNSDirector Dealings / Market Share Sale and Purchase
17th Aug 20177:00 amRNSInterim Results
11th Aug 20177:00 amRNSOXB announces Innovate UK £2m collaboration
7th Aug 20179:05 amRNSHolding(s) in Company
7th Aug 20177:00 amRNSMHRA Licence For Commercial Supply
1st Aug 20179:19 amRNSTotal Voting Rights
25th Jul 20177:00 amRNSNotice of Interim Results
24th Jul 201710:10 amRNSDirector Dealings / Market Share Purchase
18th Jul 20178:47 amRNSDirector Dealings / Market Share Sale and Purchase
14th Jul 20174:49 pmRNSDirector/PDMR Shareholding
14th Jul 20173:30 pmRNSPDMR Shareholding
14th Jul 201711:41 amRNSLTIP for Long Term Incentive Plan
13th Jul 201712:38 pmRNSDirector Dealings / Market Share Sale and Purchase
13th Jul 20177:15 amRNSHoldings in Company
13th Jul 20177:00 amRNSFDA AdCom Recommends CTL019 for Approval
11th Jul 20179:29 amRNSDirector Dealings / Market Share Sale and Purchase
7th Jul 201710:15 amRNSHardman Research: Major deal to supply Novartis
6th Jul 20177:15 amRNSHolding(s) in Company
6th Jul 20177:00 amRNSMajor Commercial and Clinical Supply Agreement
3rd Jul 20172:20 pmRNSTotal Voting Rights
3rd Jul 20172:18 pmRNSBlock Listing
30th Jun 201710:38 amRNSRefinancing of Debt Facility
23rd Jun 201710:12 amRNSDirector Dealings / Market Share Purchase
14th Jun 20173:00 pmRNSFindings from Phase II JULIET Study
7th Jun 20177:00 amRNSOXB notes FDA Advisory Committee to review CTL019
2nd Jun 20177:00 amRNSOXB to Present at Jefferies Healthcare Conference
1st Jun 201712:22 pmRNSTotal Voting Rights
24th May 20171:55 pmRNSDirector/PDMR Shareholding
23rd May 20172:03 pmRNSResult of AGM
4th May 20178:46 amRNSTotal Voting Rights
28th Apr 20177:00 amRNSAnnual Report and Accounts & AGM Notification
24th Apr 201710:17 amRNSDirector/PDMR Shareholding
4th Apr 20177:00 amRNSHolding(s) in Company
3rd Apr 20179:11 amRNSTotal Voting Rights
31st Mar 20177:15 amRNSHardman: Delivering commercial gene-therapy vector
30th Mar 20177:02 amRNSBLA filing for CTL019
27th Mar 201710:44 amRNSPublication in the Journal Nature Communications
23rd Mar 20171:47 pmRNSDirector Dealings
22nd Mar 20177:00 amRNSHolding(s) in Company
16th Mar 20177:00 amRNSPRELIMINARY RESULTS FOR THE YEAR ENDED 31 DEC 2016
10th Mar 20177:00 amRNSNotice of Preliminary Results
1st Mar 201710:24 amRNSTotal Voting Rights
28th Feb 20177:00 amRNSAppointment of New Chief Financial Officer
24th Feb 20179:36 amRNSDirector Dealings
24th Feb 20177:00 amRNSResults of TroVax® in Advanced Colorectal Cancer
1st Feb 201710:09 amRNSTotal Voting Rights
25th Jan 20179:02 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.